On behalf of Genentech, Inc., I respectfully request the NCCN NSCLC Guideline Panel to review the enclosed recent key publications for:

- **Avastin (bevacizumab):** Maintenance therapy for NSCLC


**Specific Changes:**

- **Avastin:** There are no specific changes being requested. We are providing data on Avastin in NSCLC for your review and consideration.

**FDA Clearance:**

- **Avastin is Off-label for Maintenance Therapy for NSCLC**

Please refer to the enclosed prescribing information for the full FDA-approved indications and safety information.

**Rationale:**

- **Avastin:** In the randomized, Phase III AVAPERL trial evaluating the safety and efficacy of Avastin maintenance with or without pemetrexed in nonsquamous non–small cell lung cancer (NSCLC), progression-free survival (PFS) was significantly prolonged with Avastin–pemetrexed. In an independent updated analysis of survival outcomes from AVAPERL, overall survival was found to be numerically, but not significantly longer for the Avastin-pemetrexed combination. Health-Related Quality Outcomes remained relatively stable throughout maintenance and was generally similar in both arms. The original full publication, along with publications of updated survival and quality of life
analyses have been submitted for your review and consideration. Additional Phase III data on the use of Avastin with pemetrexed in NSCLC have been reported.1-4

Respectfully submitted,

[Signature]

Supplemental References


